Key Highlights

  • Citius Pharmaceuticals posted a GAAP net loss of $0.34 per share, missing consensus by $0.09.
  • Revenue of $1.5 million missed expectations by $8.27 million.
  • The company's cash position stood at $17.0 million.
  • Citius is initiating the commercial rollout of LYMPHIR.

Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) posted third-quarter results that trailed expectations, with a GAAP net loss of $0.34 per share falling $0.09 short of consensus estimates.

What Happened

Revenue of $1.5 million missed expectations by $8.27 million, and the company's $17.0 million cash position underscores ongoing Capital requirements as it initiates the commercial rollout of LYMPHIR.

Market Reaction

The disclosed information does not include stock price or trading data for Citius Pharmaceuticals following the Q3 results.

Outlook

Continued progress on the commercial rollout of LYMPHIR, weighed against the company's $17.0 million cash position and ongoing capital requirements, is likely to remain the key Factor shaping sentiment toward Citius Pharmaceuticals' stock going forward.